The Effect of Atorvastatin on Serum Lipids, Lipoprotein(a) and Plasma Fibrinogen Levels in Primary Dyslipidaemia – A Pilot Study Involving Serial Sampling

References

• Jones, P., Kafonek, S., Laurora, I. and Hunninghake, D. for the CURVES investigators (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol., 81, 582–587.
   PubMed Web of Science ®Google Scholar
• Bairaktari, E. T., Tzallas, C. S., Tsimichodimos, V. K., Liberopoulos, E. N., Miltiadous, G. A. and Elisaf, M. S. (1999). Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J. Cardiovasc. Risk., 6, 113–116.
   PubMedGoogle Scholar
• Dahlen, G. (1994). Lp (a) lipoprotein in cardio-vascular disease. Atherosclerosis, 108, 111–126.
   PubMed Web of Science ®Google Scholar
• Scanu, A. M. (1998). Atherothrombo-genicity of lipoprotein (a): the debate. Am. J. Cardiol., 82, 26Q–33Q.
   PubMedGoogle Scholar
• Behar, S. for the BIP Study Group (1999). Lowering fibrinogen levels: clinical update. Blood Coagul. Fibrinol., 10\(Suppl 1), S41–S43.
   PubMedGoogle Scholar
• Maresca, G., Di Blasio, A., Marchioli, R. and Di Minno, G. (1999). Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb. Vasc. Biol., 19, 1368–1377.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Lumb, P. J., Semra, Y. K. and Crook, M. A. (1998). Effect of atorvastatin on plasma fibrinogen. Lancet, 351, 569–570.
   PubMed Web of Science ®Google Scholar
• Davidson, M., McKenney, J., Stein, E., Schrott, H., Bakker-Arkema, R., Fayyad, R. and Black, D. for the Atorvastatin Study Group I (1997). Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am. J. Cardiol., 79, 1475–1481.
   Google Scholar
• Nair, D. R., Papadakis, J. A., Jagroop, I. A., Mikhailidis, D. P. and Winder, A. F. (1998). Statins and fibrinogen. Lancet, 351, 1430.
   PubMed Web of Science ®Google Scholar
• Athyros, V. G., Papageorgiou, A. A., Hatzikonstantinou, H. A., Athyrou, V. V. and Kontopoulos, A. G. (1998). Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia. A pilot, randomised, double-blind, dose-titrating study. Clin. Drug. Invest., 16, 219–227.
   PubMed Web of Science ®Google Scholar
• Rosenson, R. S. and Tangney, C. C. (1998). Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. J. Am. Med. Assoc.. 279, 1643–1650.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Lumb, P. J., Semra, Y., Chik, G., Christ, E. R. and Crook, M. A. (1999). Atorvastatin compared to simvastatin-based therapies in the management of severe familial hyperlipidemias. Q. J. Med., 92, 387–394.
   Google Scholar
• Summary of the second report of the National Cholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (1993). J. Am. Med. Assoc., 269, 3015–3023.
   PubMed Web of Science ®Google Scholar
• Remmell, P. S., Gorder, D. D., Hall, Y. and Tilotson, J. L. (1980). Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). J. Am. Diet. Assoc., 76, 351–356.
   PubMed Web of Science ®Google Scholar
• Friedewald, W. T., Levy, R. I. and Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 18, 499–502.
   PubMed Web of Science ®Google Scholar
• Silberman, S. R., Armentout, M. A., Vella, F. A., Saha, A. I. and Macra, T. L. (1990). Lp(a) for quantitation of human lipoprotein (a) by enzyme linked immunoassay. UM. Chem., 36, 91.
   Google Scholar
• Montgomery, H. E., Clarkson, P., Nwose, O. M., Mikhailidis, D. P., Jagroop, I. A., Dollery, C., Moult, J., Benhizia, F., Deanfield, J., Jubb, M., World, M., McEwan, J. R., Winder, A. F. and Humphries, S. (1996). The acute rise in plasma fibrinogen with exercise is influenced by the G-453-A polymorphism of the B - fibrinogen gene. Arterioscler. Thromb. Vasc. Biol., 16, 386–391.
   PubMed Web of Science ®Google Scholar
• Alaupovic, P., Heinonen, T., Shurzinske, L. and Black, D. M. (1997). Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis, 133, 123–133.
   PubMed Web of Science ®Google Scholar
• Dart, A., Jerums, G., Nicholson, G., d'Emden, M., Hamilton-Craig, I., Tallis, G., Best, J., West, M., Sullivan, D., Bracs, P. and Black, D. (1997). A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardiol., 80, 39–44.
   PubMed Web of Science ®Google Scholar
• Garnotel, R., Monier, F., Lefevre, F. and Gillery, P. (1998). Long-term variability of serum lipoprotein (a) concentrations in healthy fertile women. Clin. Chem. Lab. Med., 36, 317–321.
   PubMed Web of Science ®Google Scholar
• Tate, J. R., Rifai, N., Berg, K., Couderc, R., Dati, R, Kostner, G. M., Sakurabayashi, I. and Steinmetz, A. (1998). International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein (a). Phase I. Evaluation of the analytical performance of lipoprotein (a) assay systems and commercial calibrators. Clin. Chem., 44, 1629–1640.
   Google Scholar
• Lippi, G. and Guidi, G. (1998). Standard-ization and clinical management of lipoprotein (a) measurements. Clin. Chem. Lab. Med., 36, 5–16.
   PubMed Web of Science ®Google Scholar
• Craig, W. and Ledue, T. (1992). The effects of long term storage on serum Lp (a) levels. Atherosclerosis, 93, 261.
   PubMed Web of Science ®Google Scholar
• Marais, A. D., Firth, J. C., Bateman, M. E., Byrnes P., Martens, C. and Mountney J. (1997). Atorvastatin: an effective agent in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 17, 1527–1532.
   PubMed Web of Science ®Google Scholar
• Bakker-Arkema, R. G., Davidson, M. H., Goldstein, R. J., Davignon, J., Isaacsohn, J. L., Weiss, S. R., Keilson, L. M., Brown, V., Miller, V. T., Shurzinske, L. J. and Black, D. (1996). Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J. Am. Med. Assoc., 275, 128–133.
   PubMed Web of Science ®Google Scholar
• Bertolotto, A., Bandinelli, S., Ruocco, L., Lo Faro, A., Penno, G. and Navalesi, R. (1999). More on the effect of atorvastatin on plasma fibrinogen levels in primary hyper-cholesterolemia. Atherosclerosis, 143, 455–457.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Lumb, P. J., Chik, G. and Crook, M. A. (1999). Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hyper-cholesterolaemia. Int. J. Clin. Pract., 53, 609–611.
   PubMed Web of Science ®Google Scholar
• Singhal, M. K., Bhaskaran, S., Szabo, T. and La Rosa, R. (1999). No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin. Petit. Dial. Int., 19, 89–91.
   PubMed Web of Science ®Google Scholar
• Dujovne, C. A., Harris, W. S., Altman, R., Overhiser, R. W. and Black, D. M. (2000). Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am. J. Cardiol., 85, 350–353.
   PubMed Web of Science ®Google Scholar
• Davis, M., Atwal, A. S., Nair, D. R., Jagroop, I. A., Seifalian, A. M., Mikhailidis, D. P. and Hamilton, G. (2000). The effect of short term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Cum Med. Res. Opin., 16, 198–204.
   PubMed Web of Science ®Google Scholar
• Wierzbicki, A. S., Crook, M. A., Nair, D. R., Mikhailidis, D. P. and Winder, A. R (2000). More on the effect of atorvastatin on plasma fibrinogen levels in primary hyper-cholesterolaemia. Atherosclerosis, 148, 204.
   PubMed Web of Science ®Google Scholar
• Breimer, L. H., Ganotakis, E. S. and Mikhailidis, D. P. (1997). Fibrinogen as a cardiovascular risk factor. Rev. Port. Cardiol., 16, 245–250.
   PubMedGoogle Scholar
• Milionis, H. J., Elisaf, M. S. and Mikhailidis, D. P. (2000). Treatment of dyslipidaemias in patients with established vascular disease: a review of the fibrates. Curr. Med. Res. Opin., 16, 21–32.
   PubMed Web of Science ®Google Scholar
• Milionis, H. J., Elisaf, M. S. and Mikhailidis, D. P. (1999). Platelets and lipid lowering interventions. Platelets, 10, 357–367.
   PubMed Web of Science ®Google Scholar